Retatrutide

Retatrutide activates GIP, GLP-1 and glucagon receptors. The receptor targets are characterized, while the contribution of each pathway to its human clinical outcomes remains uncertain.

How It Works (Simplified)

Retatrutide activates three hormone receptors; trials measure the resulting clinical effects without isolating the contribution of each receptor:

Key Research: Jastreboff AM et al. (2023) demonstrated 24.2% weight loss at 48 weeks in Phase 2. PMID:37366315

Preclinical mechanistic study: In diet-induced obese mice lacking GLP-1 receptors, retatrutide still reduced food intake and body weight, although a higher dose was needed than in wild-type mice. The same paper also tested a separate GIP/glucagon co-agonist, BWB3054; its findings are not a clinical result for retatrutide (PMID:41997446).

First published phase 3 result (TRANSCEND-T2D-1)

TRANSCEND-T2D-1, published in The Lancet on 6 June 2026, is the first phase 3 trial of retatrutide to report (PMID:42250575, NCT06354660). It ran 40 weeks at 48 sites in the USA, Mexico and India, and randomised 537 adults whose type 2 diabetes was inadequately controlled by diet and exercise alone to once-weekly retatrutide 4 mg, 9 mg or 12 mg, or placebo. Baseline mean HbA1c was 7.9% and mean BMI 35.8 kg/m².

The primary endpoint was HbA1c change at week 40, reported on the treatment-regimen estimand — the analysis that keeps every randomised participant in, regardless of whether they stayed on the drug. Mean change was -1.69% at 4 mg, -1.86% at 9 mg and -1.94% at 12 mg, against -0.81% with placebo. The corresponding differences versus placebo were -0.88% (95% CI -1.18 to -0.59), -1.04% (-1.32 to -0.76) and -1.12% (-1.39 to -0.85).

Bodyweight, a key secondary endpoint, fell 11.5%, 13.9% and 15.3% across the three doses against 2.6% with placebo. Gastrointestinal events were the most frequent adverse events and were generally mild to moderate; discontinuations for adverse events ran 2 to 5% on retatrutide and 0% on placebo. No severe hypoglycaemia was reported. Two deaths occurred, both in the 4 mg group, and both were reported as unrelated to the study drug.

This is a diabetes trial, not an obesity trial. The 15.3% weight reduction at 40 weeks came in a population selected for glycaemic control. The obesity question has since received sponsor-reported TRIUMPH results, discussed below.

Phase 2 post-hoc cardiovascular biomarkers (not TRIUMPH)

The newest verified paper, Ruotolo et al. (PMID:42608321), is a post-hoc analysis of two phase 2 randomised trials (NCT04881760, NCT04867785) using placebo-adjusted mixed models for repeated measures. It enrolled adults with obesity or overweight with type 2 diabetes (36 weeks) and without (48 weeks). Retatrutide was associated with reductions in non-HDL cholesterol (up to -21.0% and -26.9%), apolipoprotein B (-21.4% and -24.2%), total triglyceride-rich lipoprotein particles (-22.5% and -33.7%), large triglyceride-rich lipoprotein particles (-84.4% and -76.6%), triglyceride-rich lipoprotein cholesterol (-29.4% and -38.6%), total LDL particles (-19.7% and -23.5%) and small LDL particles (-32.6% and -32.3%). High-sensitivity C-reactive protein (-54.8%) and interleukin-6 (-29.6%) fell in the obesity-without-diabetes study only.

This is a biomarker analysis of phase 2 trials, not a TRIUMPH phase 3 efficacy readout, and it is not a head-to-head against tirzepatide or semaglutide.

Phase 3 Clinical Program (TRIUMPH)

TRIUMPH registrational program: The Phase 3 TRIUMPH program consists of four multicenter, randomized, double-blind trials enrolling over 5,800 participants, evaluating weekly subcutaneous retatrutide against placebo for obesity and two related complications — obstructive sleep apnea (OSA) and knee osteoarthritis (OA). It uses a basket trial design: two weight-management trials (TRIUMPH-1 and TRIUMPH-2) with OSA/OA protocols nested within, one weight-management trial in a population with cardiovascular disease (TRIUMPH-3), and one stand-alone knee OA trial (TRIUMPH-4). The primary weight-management endpoint is percent change in body weight. PMID:41090431

Sponsor-reported results, not yet peer-reviewed Phase 3 obesity papers: Lilly reported TRIUMPH-4 in December 2025, TRIUMPH-1 in May 2026, and TRIUMPH-2 and -3 in July 2026. In TRIUMPH-1 (NCT05929066), the 80-week treatment-regimen mean weight change at the highest studied strength was −25.0% versus −3.9% with placebo; the larger −28.3% versus −2.2% figures use an efficacy estimand that excludes some effects of discontinuation (Lilly, 21 May 2026). In TRIUMPH-2, Lilly reported −20.8% versus −4.0% with placebo at 80 weeks in adults with obesity and type 2 diabetes, and in TRIUMPH-3 −22.6% versus −3.2% in adults with severe obesity and established cardiovascular disease; those percentages use the efficacy estimand (Lilly, 23 July 2026). Earlier TRIUMPH-4 topline reported −28.7% versus −2.1% at 68 weeks in adults with obesity and knee osteoarthritis, also using the efficacy estimand (Lilly, 11 December 2025). These populations and estimands differ, so their percentages are not a head-to-head ranking.

In TRIUMPH-1, Lilly reported adverse-event discontinuations of 11.3% at the highest strength versus 4.9% with placebo, and dysesthesia of 12.5% versus 0.9%. TRIUMPH-3’s exploratory cardiovascular event estimates were imprecise: MACE-3 hazard ratio 1.12 (95% CI 0.64 to 1.96), which does not establish benefit or harm. A dedicated cardiovascular outcomes trial remains necessary. Lilly said it plans an FDA biologics license application in Q1 2027; this is a future plan, not a submitted application or approval.

Important Limitations

• Retatrutide is an investigational drug not yet approved by FDA/EMA
• Phase 3 obesity toplines are sponsor-reported; detailed peer-reviewed results and registry tables for the TRIUMPH trials were not located in this review
• Safety beyond trial follow-up and rare adverse events remain uncertain
• Gastrointestinal adverse events were dose-related and the most common in Phase 2 trials
• Dedicated cardiovascular, kidney, and hepatic outcomes remain unsettled; TRIUMPH-3 exploratory cardiovascular event estimates are inconclusive
• Head-to-head comparisons against approved incretin therapies are not yet published